Achieve Life Sciences is trading 11.5% up at $7.25 in pre-market on October 23, following positive 52-week ORCA-OL cytisinicline trial results announced October 21; available reporting does not establish that the update directly caused the morning’s rise.
- The study reported 31.2% four-week sustained abstinence during the final four weeks of treatment.
- No new safety signals were identified. Broader markets were weaker and do not appear to explain the positive move.